Conference Proceedings
Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse
Chun Yew Fong, George Grigoriadis, Jay Hocking, Philip Campbell, Anthony P Schwarer, Patricia A Walker, Sharon Avery, Sushrut S Patil, Hatem H Salem, Andrew Spencer, Andrew H Wei
BLOOD | AMER SOC HEMATOLOGY | Published : 2011
Abstract
Abstract Abstract 3631 Introduction: Despite improvements in clinical outcome with intensification of induction and consolidation chemotherapy, the majority of patients with AML will ultimately relapse. At first relapse, the European Prognostic Index (EPI) stratifies outcome according to relapse-free interval, karyotype, age and prior allogeneic stem cell transplant (Breems et al, JCO 2005; 1969). Recently, FLT3-ITD has also emerged as a predictor of poor outcome in relapsed patients (Chevallier et al, Leukemia 2011; 939). The purpose of this study was to define predictors of outcome in patients with AML treated at first rela..
View full abstract